Figure 4.
Neutralization of SARS-CoV-2 Omicron variants by individual human sera collected from post-third-dose monovalent mRNA vaccine recipients. Individual sera (each represented by a circle) collected from volunteers (no prior SARS-CoV-2 infection) who received three doses of the original mRNA monovalent vaccine (Moderna or Pfizer-BioNTech) were analyzed against SARS-CoV-2 614D virus (N = 20) and Omicron variants BA.1 (N = 20), BA.2 (N = 20), BA.2.12.1 (N = 20) and BA.4/5 (N = 13) using the FRNT assay. All viruses were isolated from clinical specimens. Bars represent GMT with 95% confidence intervals. Significance relative to 614D or BA.4/5 was determined by one-way repeated measures ANOVA with Dunnett correction on log transformed neutralization titers. p values are displayed as * p ≤ 0.05, *** p ≤ 0.001, **** p ≤ 0.0001 and not significant (ns) p > 0.05. GMT and fold change compared to the 614D reference virus are displayed at the top of the plots. The dashed line represents the limit of detection at FRNT50 of 10.